FY2024 EPS Estimates for Vaxart, Inc. (NASDAQ:VXRT) Lifted by Analyst

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Vaxart in a note issued to investors on Thursday, August 22nd. Cantor Fitzgerald analyst C. Duncan now anticipates that the biotechnology company will earn ($0.45) per share for the year, up from their prior estimate of ($0.54). The consensus estimate for Vaxart's current full-year earnings is ($0.55) per share.

Vaxart (NASDAQ:VXRT - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). Vaxart had a negative net margin of 920.00% and a negative return on equity of 121.06%. The company had revenue of $6.40 million during the quarter, compared to analyst estimates of $65.70 million. During the same quarter last year, the company posted ($0.16) EPS.

Separately, Oppenheimer assumed coverage on shares of Vaxart in a research report on Thursday, August 15th. They set an "outperform" rating and a $4.00 target price on the stock.

Vaxart Stock Performance

VXRT traded down $0.07 on Monday, reaching $0.88. The company had a trading volume of 2,421,557 shares, compared to its average volume of 2,892,882. Vaxart has a fifty-two week low of $0.52 and a fifty-two week high of $1.54. The stock has a market cap of $155.81 million, a P/E ratio of -1.66 and a beta of 0.65. The company's fifty day moving average is $0.70 and its 200 day moving average is $0.89.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new position in shares of Vaxart during the 1st quarter worth approximately $20,000,000. Vanguard Group Inc. boosted its position in shares of Vaxart by 19.9% during the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company's stock worth $10,984,000 after acquiring an additional 1,404,391 shares in the last quarter. Millennium Management LLC boosted its position in shares of Vaxart by 110.8% during the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock worth $2,660,000 after acquiring an additional 2,095,274 shares in the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Vaxart during the 2nd quarter worth approximately $402,000. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Vaxart during the 2nd quarter worth approximately $65,000. Institutional investors and hedge funds own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.